Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

Journal of Infectious Diseases

Volumn 182, Issue 1, 2000, Pages 326-329

  Jacobson, Jeffrey M ^a   Lowy, Israel ^a   Fletcher, Courtney V ^d   Neill, Tobias J ^c   Tran, Diep N H ^c   Ketas, Thomas J ^b   Trkola, Alexandra ^b   Klotman, Mary E ^a   Maddon, Paul J ^c   Olson, William C ^c   Israel, Robert J ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c Clinical Research   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 IMMUNOGLOBULIN G2; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHO CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANTI-HIV AGENTS; CD4 IMMUNOADHESINS; HIV INFECTIONS; HIV-1; HUMANS; INFUSIONS, INTRAVENOUS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 0033914939     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315698     Document Type: Article

References (15)

1. 1. Allaway GP, Davís-Bruno KL, Beaudry GA, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res Hum Retroviruses 1995; 11:533-9.
2. 2. Trkola A, Ketas T, KewalRamani VN, et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998; 72: 1876-85.
3. 3. Trkola A, Pomales AP, Yuan H, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG2. J Virol 1995; 69:6609-17.
4. 4. Gauduin MC, Allaway GP, Maddon PJ, Barbas CF 3, Burton DR, Koup RA. Effective ex vivo neutralization of plasma HIV-1 by recombinant immunoglobulin molecules. J Virol 1996; 70:2586-92.
5. 5. Gauduǐn MC, Allaway GP, Olson WC, Weir R, Maddon PJ, Koup RA. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. J Virol 1998; 72: 3475-8.
6. 6. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J Virol 1997; 71: 2779-85.
7. 7. Gibaldi M, Perrier D. Pharmacokinetics. 2d ed. New York: Marcel Dekker, 1982.
8. 8. Trkola A, Paxton WA, Monard SP, et al. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol 1998; 72:396-404.
9. 9. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
10. 10. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-22.
11. 11. Cole MS, Anasetti C, Tso JY. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J Immunol 1997; 159:3613-21.
12. 12. Schacker T, Coombs RW, Collier AC, et al. The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. J Infect Dis 1994; 169:37-40.
13. 13. Schacker T, Collier AC, Coombs R, et al. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:145-52.
14. 14. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-7.
15. 15. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93:681-4.